Wedbush reaffirms "outperform" rating, raising target price for IGM Biosciences to $20.00, implying a 114.13% upside.
Wedbush reiterates "outperform" rating for IGM Biosciences (NASDAQ:IGMS), setting a $20.00 price target, representing a potential upside of 114.13%. Royal Bank of Canada upgraded shares from "sector perform" to "outperform," targeting $21.00. HC Wainwright maintained a "neutral" rating with a $12.00 target price. Marketbeat.com reports a consensus rating of "Moderate Buy" with an average price target of $17.89.
May 11, 2024
5 Articles